Post‐Liver Transplantation–Burkitt Lymphoma in Children: A Single‐Center Study of Clinical Characteristics, Treatment, and Outcomes
- 6 February 2025
- journal article
- research article
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (2) , e70027
Abstract
Background: Post‐liver transplantation–Burkitt lymphoma (PLT‐BL) is an aggressive and life‐threatening complication after pediatric liver transplantation. The research on the disease characteristics, treatment, and prognosis of pediatric PLT‐BL is limited.Methods: A retrospective, observational study was performed to analyze the disease characteristics, treatment, and outcomes in 12 pediatric liver transplant (LT) recipients diagnosed with PLT‐BL.Results: The medium time from liver transplantation to diagnosis was 32.71 months (range, 25.78–37.85 months). All patients (100%) tested positive for EBV viremia at diagnosis. Abdomen and peripheral lymph nodes were the most frequently involved sites (11 [91.66%] and 10 [83.33%], respectively). Three pediatric patients were diagnosed as relapsed or refractory PLT‐BL and treated with chimeric antigen receptor (CAR) T‐cell therapy, and two of them achieved complete remission (CR). Nine patients were alive with CR at the last follow‐up. Three deaths were attributed to progression and tumor lysis syndrome, characterized by significantly elevated lactate dehydrogenase (LDH) levels (p = 0.027), more advanced tumor stages (p = 0.045), and an increased number of involved sites (p = 0.009). With a median follow‐up of 2.7 years after diagnosis, the event‐free survival (EFS) and overall survival (OS) rates for PLT‐BL patients were 66.7% and 74.1%, respectively. In four patients, immunosuppression was successfully withdrawn and they maintained tolerance status.Conclusion: Elevated LDH levels, more advanced tumor stages, and increased number of involved sites are potentially associated with poor outcome. Immunosuppression withdrawal is a safe and feasible approach for PLT‐BL.Keywords
Funding Information
- National Key Research and Development Program of China
This publication has 30 references indexed in Scilit:
- Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphomaVirchows Archiv, 2022
- A prospective multicenter study investigating rituximab combined with intensive chemotherapy in newly diagnosed pediatric patients with aggressive mature B cell non-Hodgkin lymphoma (CCCG-BNHL-2015): a report from the Chinese Children’s Cancer GroupAnnals of Hematology, 2022
- Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short‐course EPOCH regimens are safe and effectivePediatric Blood & Cancer, 2021
- Post‐transplant Lymphoproliferative Disorders After Liver Transplantation: A Retrospective Cohort Study Including 1954 TransplantsLiver Transplantation, 2021
- Treatment of childhood cancer in China: Current status and future directionPediatric Investigation, 2020
- Risk of lymphoma subtypes after solid organ transplantation in the United StatesBritish Journal of Cancer, 2013
- Burkitt lymphoma risk in U.S. solid organ transplant recipientsAmerican Journal of Hematology, 2012
- Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trialThe Lancet Oncology, 2012
- Post‐transplant Burkitt lymphoma is a more aggressive and distinct form of post‐transplant lymphoproliferative disorderCancer, 2011
- REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPYThe Lancet, 1984